Medication Comparison · Updated November 2026

Mounjaro vs Ozempic vs Wegovy vs Zepbound: Complete 2026 Comparison

Four GLP-1 medications, two molecules, and a lot of confusion. I have been on Mounjaro since 2024 and track my results with DEXA scans. This comparison breaks down efficacy, cost, side effects, and insurance for all four drugs so you can figure out which one actually makes sense for you.

The Short Version

• Mounjaro (tirzepatide) and Zepbound (also tirzepatide) are the same molecule. Mounjaro is approved for type 2 diabetes. Zepbound is approved for weight management.
• Ozempic (semaglutide) and Wegovy (also semaglutide) are the same molecule. Ozempic is approved for type 2 diabetes. Wegovy is approved for weight management.
• Tirzepatide (Mounjaro/Zepbound) produces more weight loss than semaglutide (Ozempic/Wegovy) in the head-to-head SURMOUNT-5 trial: 20.2% vs 13.7% of body weight at 72 weeks.
• Self-pay prices fell. Without insurance, the makers now sell these drugs direct for about $299 to $499 a month depending on drug and dose (checked Nov 4, 2026). Routine compounded copies lost their legal basis in 2025.
• Side effects are similar across all four, mostly GI (nausea, constipation, diarrhea), typically worst in the first few weeks of each dose increase.

What Each Medication Actually Is

The first thing to understand is that there are really only two molecules here, sold under four brand names.

Tirzepatide (Mounjaro & Zepbound)

Tirzepatide is a dual GIP/GLP-1 receptor agonist made by Eli Lilly. In plain terms: it activates two hormones involved in blood sugar regulation and appetite, specifically GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).

Think of it like having two keys turning two locks at once. GLP-1 slows gastric emptying, reduces appetite, and improves insulin sensitivity. GIP adds additional appetite suppression and may play a role in how your body stores and burns fat.

• Mounjaro is FDA-approved for type 2 diabetes (May 2022). Its label also covers lowering heart attack, stroke and cardiovascular death risk in high-risk adults with type 2 diabetes. Prescribed off-label for weight loss.
• Zepbound is FDA-approved for chronic weight management (November 2023) and for moderate to severe obstructive sleep apnea in adults with obesity. Same drug, same dose strengths, different label.

Available doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (weekly injection).

Semaglutide (Ozempic & Wegovy)

Semaglutide is a GLP-1 receptor agonist made by Novo Nordisk. It targets one hormone, GLP-1, which slows digestion, reduces hunger signals to the brain, and improves how your body handles insulin.

• Ozempic is FDA-approved for type 2 diabetes (December 2017). Widely prescribed off-label for weight loss.
• Wegovy is FDA-approved for chronic weight management (June 2021). Same active ingredient, higher maximum dose, and now a daily pill.

Ozempic doses: 0.25 mg, 0.5 mg, 1 mg, 2 mg (weekly injection). Wegovy doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg and 7.2 mg (Wegovy HD) weekly injection, or 1.5 mg to 25 mg daily tablets, per the Wegovy label.

The Key Difference: Dual Action vs Single Action

The core distinction is that tirzepatide works on two receptors (GIP + GLP-1) while semaglutide works on one (GLP-1 only). This dual mechanism is widely believed to explain why tirzepatide produces greater weight loss in clinical trials. The GIP receptor activation appears to enhance fat metabolism and appetite suppression beyond what GLP-1 alone achieves.

Weight Loss Efficacy: What the Clinical Trials Show

This is where the data gets compelling. Both drugs produce significant weight loss, but tirzepatide has a clear edge.

SURMOUNT Trials (Tirzepatide / Mounjaro / Zepbound)

The SURMOUNT-1 trial (published in the New England Journal of Medicine, 2022) studied tirzepatide in adults with obesity or overweight (BMI ≥ 30, or ≥ 27 with a weight-related condition) who did not have diabetes.

Results at 72 weeks:

• 5 mg dose: 15.0% body weight loss
• 10 mg dose: 19.5% body weight loss
• 15 mg dose: 20.9% body weight loss
• Placebo: 3.1% body weight loss

57% of participants on the 15 mg dose lost 20% or more of their body weight, compared with 3% on placebo.

STEP Trials (Semaglutide / Wegovy)

The STEP 1 trial (also published in the New England Journal of Medicine, 2021) studied semaglutide 2.4 mg in a similar population: adults with obesity or overweight without diabetes.

Results at 68 weeks:

• 2.4 mg dose: 14.9% body weight loss
• Placebo: 2.4% body weight loss

Half of participants on semaglutide (50.5%) lost 15% or more of their body weight.

Head-to-Head: SURMOUNT-5

The SURMOUNT-5 trial directly compared tirzepatide (up to 15 mg) against semaglutide (up to 2.4 mg) over 72 weeks in adults with obesity.

Results:

• Tirzepatide group: 20.2% body weight loss
• Semaglutide group: 13.7% body weight loss

This was a statistically significant difference. Tirzepatide produced roughly 47% more weight loss than semaglutide when compared directly.

Weight Loss Comparison Table

Important context: STEP 8 compared semaglutide 2.4 mg with daily liraglutide, not Ozempic. Ozempic’s weight results come from diabetes trials and are smaller. These are averages. Individual results vary significantly based on dose, diet, exercise, starting weight, and how long you stay on treatment. Some people respond better to semaglutide than tirzepatide, and vice versa.

Cost Comparison: Self-Pay Prices (Nov 4, 2026)

Cost is the single biggest factor for most people. Both makers now sell direct to cash-pay patients. Here is what their own pages listed on November 4, 2026.

With commercial insurance that covers the drug, both makers offer savings cards that can bring the copay as low as $25 a month for eligible patients. Government plan members (Medicare, Medicaid and others) are excluded from these cards.

A Note on Compounded GLP-1s

Compounding pharmacies made large volumes of tirzepatide and semaglutide copies while the drugs were on FDA’s shortage list. FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. The grace periods ended by March 19, 2025 for tirzepatide and May 22, 2025 for semaglutide. 503B outsourcing facilities can no longer make copies, and 503A pharmacies may do so only in narrow, patient-specific cases.

FDA does not review compounded drugs for safety, effectiveness or quality before they are sold. If a provider still offers a compounded version, ask which pharmacy makes it and what legal pathway it relies on. See our compounded semaglutide and compounded tirzepatide pages for current prices.

Side Effects Comparison

The side effect profiles of tirzepatide and semaglutide are similar because they share the GLP-1 mechanism. Most side effects are gastrointestinal and tend to be worst during dose escalation.

Common Side Effects (Both Medications)

• Nausea is the most frequently reported side effect. Usually peaks in the first 1-2 weeks after each dose increase and subsides.
• Diarrhea is more common in the early weeks.
• Constipation. Some people get the opposite GI issue. Fiber and hydration help. See GLP-1 constipation: what works.
• Decreased appetite. This is the point, but it can feel extreme early on.
• Injection site reactions such as mild redness or itching at the injection site. Usually minor.
• Fatigue. Some people report tiredness, especially in the first few weeks.

Differences Between the Two

In the head-to-head SURMOUNT-5 trial, the most common side effects with both drugs were gastrointestinal and mostly mild to moderate. In the separate placebo-controlled trials, 4.3% to 7.1% of tirzepatide patients in SURMOUNT-1 and 4.5% of semaglutide patients in STEP 1 (for GI events) stopped treatment because of side effects.

From personal experience on tirzepatide: the nausea was real but manageable in the first week or two of each dose increase. Eating smaller meals, staying hydrated, and not eating too quickly made a significant difference. By week 3-4 at each dose, side effects were minimal.

Serious Side Effects (Rare but Important)

Both medications carry warnings for:

• Pancreatitis is rare but reported. Seek medical attention for severe, persistent abdominal pain.
• Gallbladder issues. Rapid weight loss itself can increase gallstone risk.
• Thyroid C-cell tumors have been seen in rodent studies. Both drugs carry a boxed warning. They are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
• Hypoglycemia. Risk is higher if combined with insulin or sulfonylureas.

Talk to your doctor about your full medical history before starting any GLP-1 medication. This article is for informational purposes and is not medical advice.

Insurance Coverage Differences

Insurance coverage varies enormously depending on your plan, employer, and state. Here’s the general picture:

Mounjaro (Diabetes Indication)

Most insurance plans cover Mounjaro for type 2 diabetes since it has a diabetes-specific FDA approval. Coverage for weight loss (off-label) is inconsistent. Some plans cover it. Many don’t.

Zepbound (Weight Management Indication)

Coverage is growing but still limited. Many employer plans exclude anti-obesity medications. Zepbound also has a sleep apnea indication, which can matter for coverage. Medicare rules for these drugs are changing, so check our Medicare guide for the current picture.

Ozempic (Diabetes Indication)

Broad insurance coverage for type 2 diabetes. It has been FDA-approved since December 2017. Off-label weight loss coverage varies by plan.

Wegovy (Weight Management Indication)

Wegovy has been approved longer than Zepbound and has a cardiovascular risk reduction indication based on the SELECT trial, which can help with coverage for people with heart disease.

Tips for Getting Coverage

1. Get a prior authorization. Your prescriber may need to submit clinical documentation.
2. Check your formulary. Call your insurance company or look online to see which GLP-1s are covered and at what tier.
3. Ask about step therapy. Some plans require you to try a cheaper medication first (like metformin or naltrexone/bupropion).
4. Appeal denials. If you’re denied, ask your provider to submit a peer-to-peer review or a formal appeal with supporting clinical evidence.
5. Consider the manufacturer savings programs discussed above if your copay is still high.

How to Get GLP-1 Medications Online

Telehealth has made access to these medications much easier. Several platforms now offer GLP-1 prescriptions with online consultations. Here are the major players:

Ro (ro.co)

Ro lists its Body Program at $149/month plus medication for brand-name GLP-1s (checked Nov 4, 2026). The program includes an online evaluation, clinician support and insurance help.

Hims & Hers (hims.com / hers.com)

Hims and Hers run online weight loss programs with clinician check-ins and home delivery. We could not confirm their current medication list or prices on November 4, 2026, so check their sites directly.

MEDVi

MEDVi sells compounded GLP-1 programs. Its landing page listed tirzepatide at $166 to $199 a month on November 4, 2026. Read our MEDVi review and our fat loss vs weight loss guide.

What to Look for in a Telehealth Provider

• Licensed prescribers. Make sure you’re seeing a licensed physician, NP, or PA.
• Compounding pharmacy and legal basis. If they offer a compounded drug, ask for the pharmacy name and license. Since 2025, copies come only from 503A pharmacies (state-regulated) in narrow cases.
• Ongoing support. Dose adjustments, check-ins, and lab work matter. Avoid providers that just ship medication with no follow-up.
• Transparent pricing. Watch out for hidden consultation fees, mandatory subscriptions, or inflated medication costs.

Which One Should You Choose?

There’s no single right answer, but here’s how to think through it:

Choose Mounjaro or Zepbound (Tirzepatide) If:

• Maximum weight loss is your priority. Tirzepatide consistently outperforms semaglutide in trials.
• You have type 2 diabetes. In SURPASS-2, tirzepatide lowered A1C by 2.01 to 2.30 percentage points over 40 weeks, compared with 1.86 for semaglutide 1 mg. Mounjaro has the diabetes indication. The diabetes and weight-loss labels also follow different insurance paths, which I break down in diabetes vs weight-loss GLP-1 prescriptions.
• You can access it affordably. Through insurance or Lilly’s self-pay and savings programs.
• You’ve plateaued on semaglutide. Some people switch to tirzepatide after stalling on Ozempic/Wegovy and see renewed progress.

Choose Ozempic or Wegovy (Semaglutide) If:

• Cardiovascular protection matters. The SELECT trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in adults with overweight or obesity and established cardiovascular disease who did not have diabetes. Tirzepatide’s heart outcomes trial, SURPASS-CVOT, was in people with type 2 diabetes. Per the Mounjaro label, it was non-inferior to dulaglutide, another GLP-1 drug, with a hazard ratio of 0.92, and superiority was not established. There is no SELECT-style trial result for tirzepatide in people without diabetes yet.
• Your insurance covers it. Semaglutide products, particularly Ozempic, tend to have broader formulary coverage.
• You prefer a longer track record. Semaglutide was first approved in December 2017, more than four years before tirzepatide.
• You want a pill. The Wegovy pill starts at $149 a month self-pay. Tirzepatide is injection-only.

Mounjaro vs Zepbound: Does It Matter Which One?

Same drug. The only difference is the FDA-approved indication and how your insurance classifies it. If you have type 2 diabetes, Mounjaro may be easier to get covered. If your primary goal is weight loss and you don’t have diabetes, Zepbound is the on-label option. Your prescriber can advise on which to pursue based on your insurance situation.

Ozempic vs Wegovy: Does It Matter Which One?

Again, same drug. Wegovy goes up to 2.4 mg, or 7.2 mg with Wegovy HD (vs Ozempic’s max of 2 mg), and has the weight management indication. For weight loss, Wegovy is the on-label choice. For diabetes, it’s Ozempic. In practice, many people use Ozempic off-label for weight loss because of better insurance coverage for the diabetes indication.

The Bottom Line

If you’re choosing between these medications, here’s my honest take:

Tirzepatide (Mounjaro/Zepbound) is the more effective drug for weight loss. The clinical data is clear, and the head-to-head SURMOUNT-5 trial confirmed it. If you can access it at a price you can afford, it’s the stronger option.

Semaglutide (Ozempic/Wegovy) is a strong option with the cardiovascular data edge for people without diabetes. It has been on the market since 2017. If you have heart disease risk factors, the SELECT trial data is meaningful. And if your insurance covers Ozempic or Wegovy but not Mounjaro or Zepbound, semaglutide is still a very effective choice.

Cost usually makes the decision. Most people end up on whichever medication they can actually afford and access consistently. An effective GLP-1 you can stay on is better than a theoretically superior one you can’t afford or can’t get.

Whatever you choose, pair it with strength training, enough protein (ask your clinician or a dietitian for a target, especially if you have kidney disease), and regular monitoring. The medication handles appetite. You still need to handle the rest.

I track my own progress with DEXA scans to make sure I’m losing fat and preserving lean mass. If you’re on a GLP-1, I’d strongly encourage some form of body composition tracking beyond just the scale. The scale doesn’t tell you what kind of weight you’re losing.

Frequently Asked Questions

Is Mounjaro the same as Zepbound?

Yes. Mounjaro and Zepbound both contain tirzepatide, made by Eli Lilly. The only difference is the FDA-approved indication. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. Same molecule and dose strengths. Zepbound is also sold in vials and KwikPens.

Can I switch from Ozempic to Mounjaro?

Yes, many people switch. Your prescriber will typically start you at a lower dose of tirzepatide (2.5 mg) even if you were on a higher dose of semaglutide, then titrate up. The two drugs have different receptor profiles, so your body needs time to adjust. Discuss timing and dosing with your provider.

How long does it take to see results?

Most people notice appetite suppression within the first 1-2 weeks. Visible weight loss typically begins within the first month. The clinical trials measured outcomes at 68-72 weeks, and weight loss was progressive throughout, meaning you keep losing weight over time as long as you continue treatment and titrate up in dose.

What happens if I stop taking GLP-1 medication?

Clinical data shows that most people regain a significant portion of lost weight after stopping GLP-1 medications. The STEP 1 extension showed that participants regained about two-thirds of their lost weight within one year of stopping semaglutide. This is why many clinicians view these as long-term medications, similar to blood pressure or cholesterol drugs. That said, some people use GLP-1s as a bridge: losing weight, building sustainable habits, and then tapering off with close monitoring.

Are compounded GLP-1 medications safe?

FDA does not review compounded drugs for safety, effectiveness or quality before they are sold, and it has received hundreds of adverse event reports tied to compounded semaglutide and tirzepatide, some linked to dosing errors. Since 2025, 503B outsourcing facilities can no longer legally make copies. Avoid overseas sellers or any provider that does not require a prescription. FDA has also warned about counterfeit Ozempic in the US supply.

Do GLP-1 medications cause muscle loss?

GLP-1 medications cause weight loss, and any significant weight loss (whether from medication, surgery, or diet) involves some loss of lean mass alongside fat. A meaningful share of the weight lost on GLP-1s can be lean mass. This is why resistance training and adequate protein intake are critical. Strength training signals your body to preserve muscle. Protein provides the building blocks. If you’re on a GLP-1, these aren’t optional. They’re essential.

Last updated: November 2026. Pricing and availability may change. This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.

What we checked

This AI-assisted public-source desk check reviewed the Mounjaro, Zepbound and Wegovy prescribing information, FDA approval records and compounding pages, the SURMOUNT-1, SURMOUNT-5, STEP 1, STEP 8, SURPASS-2, SELECT and STEP 1 extension trial publications, Lilly and NovoCare self-pay price pages, and the Ro and MEDVi pricing pages on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.